Loading...
Market
What will be the regulatory approval status of Pfizer's once-daily Danuglipron by the end of 2025?
2
Resolution / Starting Odds
Approved in the US • 25%
Approved in the EU • 25%
Approved in both US and EU • 25%
Not approved • 25%
Regulatory filings and announcements from Pfizer
Story
Pfizer Advances Development of Once-Daily Weight-Loss Pill Danuglipron with Dose Optimization Studies in 2024
Jul 11, 2024, 12:04 PM
Pfizer Inc has announced plans to advance the development of a once-daily formulation of its experimental obesity pill, danuglipron. The company will conduct dose optimization studies in the second half of 2024 following promising pharmacokinetic results from early-stage trials. This move comes after Pfizer scrapped a twice-daily version of the drug late last year. The reworked once-daily modified release version aims to capture a share of the lucrative multibillion-dollar market for obesity medications. Danuglipron is an oral GLP-1 receptor agonist, a class of drugs known for their efficacy in weight loss. Pfizer's decision to proceed with the once-daily formulation reflects its commitment to addressing obesity, a significant public health issue.
View original story
Similar markets
Successful with significant efficacy • 25%
Successful with moderate efficacy • 25%
Unsuccessful due to adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
First half of 2025 • 25%
Second half of 2025 • 25%
2026 • 25%
2027 or later • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
FDA Approval • 25%
EMA Approval • 25%
Additional Phase 3 Trials • 25%
Other • 25%
Approved • 25%
Rejected • 25%
Pending • 25%
Withdrawn • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Approved in USA only • 25%
Approved in EU only • 25%
Approved in both USA and EU • 25%
Not approved in USA or EU • 25%
SMA Type 3 • 25%
SMA Type 2 • 25%
Both SMA Type 2 and 3 • 25%
Other • 25%
Approved in UK only • 25%
Approved in UK and EU • 25%
Approved in UK, EU, and USA • 25%
Not approved in any major market • 25%
FDA approval • 25%
FDA rejection • 25%
Conditional approval • 25%
No decision • 25%